Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Shareholders appeared unconcerned with Astellas Pharma Inc.'s (TSE:4503) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

Check out our latest analysis for Astellas Pharma

The Impact Of Unusual Items On Profit

For anyone who wants to understand Astellas Pharma's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by JP¥58b due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. Astellas Pharma took a rather significant hit from unusual items in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Astellas Pharma's Profit Performance

As we discussed above, we think the significant unusual expense will make Astellas Pharma's statutory profit lower than it would otherwise have been. Because of this, we think Astellas Pharma's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! On the other hand, its EPS actually shrunk in the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Astellas Pharma as a business, it's important to be aware of any risks it's facing. Case in point: We've spotted 3 warning signs for Astellas Pharma you should be mindful of and 1 of these is significant.

Today we've zoomed in on a single data point to better understand the nature of Astellas Pharma's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.